Press Release: PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels

Author (Corporate)
Series Title
Series Details EMA/618574/2013 (08.11.13)
Publication Date 08/11/2013
Content Type

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), on 8 November 2013, recommended that medicines containing acipimox should have their marketing authorisations amended to ensure that they are used across the European Union only as an additional or alternative treatment in type IIb and type IV hyperlipoproteinaemia. These are conditions involving hypertriglyceridaemia (high levels of triglycerides, a type of fat, in the blood), with or without increased cholesterol.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001948.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release; EMA/618574/2013 (08.11.13): PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500154014.pdf
Subject Categories
Countries / Regions